Long non‑coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells

Yang,Yuting; Dai,Wenshu; Sun,Yingwei; Zhao,Ziyi

doi:10.3892/or.2019.6991

Long non‑coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells

Authors:
- Yuting Yang
- Wenshu Dai
- Yingwei Sun
- Ziyi Zhao
View Affiliations

Affiliations: Department of Scientific Research, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, School of Biomedical Science, The University of Queensland, Brisbane St Lucia, QLD 4072, Australia, Department of Pharmacy, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, Central Laboratory, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China
Published online on: January 31, 2019 https://doi.org/10.3892/or.2019.6991
Pages: 2311-2320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) are known to be involved in the processes of tumourigenesis and malignant behaviours in many types of cancer, including acute myeloid leukaemia (AML). Accumulating evidence has revealed that novel lncRNAs exerted critical roles in these processes. In the present study, we investigated the effects of lncRNA linc00239 (NR_026774.1), which is 662 φnucleotides (nt) in length and was found to be upregulated in AML patients, on malignant behaviours and chemosensitivity in AML cells, including KG‑1 and HL‑60. linc00239 expression was detected in KG‑1 and HL‑60 cells by quantitative PCR and northern blotting, and it was found that linc00239 is detectable by both of these assays. After knockdown or overexpression of linc00239 in AML cells, the results revealed that the presence of linc00239 promoted proliferation, colony formation and migration ability. Furthermore, the presence of linc00239 increased chemoresistance to doxorubicin in AML cells partially by preventing doxorubicin‑induced apoptotic cell death. It was also determined that the presence of linc00239 was related to activation of the phosphatidylinositol 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Inhibition of PI3K/Akt/mTOR using 1 µM NVP‑BEZ235 (BEZ) abolished the inhibitory effect of linc00239 on chemosensitivity and the preventative effect on doxorubicin‑induced cell death. Collectively, our data revealed that linc00239 is a novel tumour promoter in AML cells and indicated that it is a potential therapeutic target.

View Figures

View References

1	Troy JD, Atallah E, Geyer JT and Saber W: Myelodysplastic syndromes in the United States: An update for clinicians. Ann Med. 46:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
2	Daver N and Cortes J: Molecular targeted therapy in acute myeloid leukemia. Hematology. 17 (Suppl 1):S59–S62. 2012. View Article : Google Scholar : PubMed/NCBI
3	Stone R, Sekeres M and Garcia-Manero G: Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol. 7:1–14. 2009.PubMed/NCBI
4	Buitenhuis M and Coffer PJ: The role of the PI3K-PKB signaling module in regulation of hematopoiesis. Cell Cycle. 8:560–566. 2009. View Article : Google Scholar : PubMed/NCBI
5	Fruman DA and Rommel C: PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov. 13:140–156. 2014. View Article : Google Scholar : PubMed/NCBI
6	Martelli AM, Evangelisti C, Chiarini F and McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 1:89–103. 2010.PubMed/NCBI
7	Altman JK, Sassano A and Platanias LC: Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget. 2:510–517. 2011. View Article : Google Scholar : PubMed/NCBI
8	Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH and Vellenga E: Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 18:103–112. 2004. View Article : Google Scholar : PubMed/NCBI
9	Xu Q, Simpson SE, Scialla TJ, Bagga A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
10	Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, Bellacosa A, Capitani S and Martelli AM: The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res. 1:234–246. 2003.PubMed/NCBI
11	Kentsis A, Topisirovic I, Culjkovic B, Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
12	Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr and Borden KL: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, et al: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 16:5424–5435. 2010. View Article : Google Scholar : PubMed/NCBI
14	Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S and Platanias LC: Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 17:4378–4388. 2011. View Article : Google Scholar : PubMed/NCBI
15	Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, et al: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 22:1698–1706. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, et al: Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120:2679–2689. 2012. View Article : Google Scholar : PubMed/NCBI
17	Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, et al: Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia. 22:147–160. 2008. View Article : Google Scholar : PubMed/NCBI
18	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
19	Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
20	Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, et al: Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci USA. 111:18679–18684. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wu S, Zheng C, Chen S, Cai X, Shi Y, Lin B and Chen Y: Overexpression of long non-coding RNA HOTAIR predicts a poor prognosis in patients with acute myeloid leukemia. Oncol Lett. 10:2410–2414. 2015. View Article : Google Scholar : PubMed/NCBI
22	Mer AS, Lindberg J, Nilsson C, Klevebring D, Wang M, Grönberg H, Lehmann S and Rantalainen M: Expression levels of long non-coding RNAs are prognostic for AML outcome. J Hematol Oncol. 11:522018. View Article : Google Scholar : PubMed/NCBI
23	Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan G and Jiang Y: HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 7:14429–14440. 2016.PubMed/NCBI
24	Yao X, Yan C, Zhang L, Li Y and Wan Q: LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis. Medicine. 97:e04732018. View Article : Google Scholar : PubMed/NCBI
25	Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, Dalla-Favera R, Tsirigos A and Aifantis I: Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 158:593–606. 2014. View Article : Google Scholar : PubMed/NCBI
26	Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al: The sequence of the human genome. Science. 291:1304–1351. 2001. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Bhan A and Mandal SS: Long noncoding RNAs: Emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 9:1932–1956. 2014. View Article : Google Scholar : PubMed/NCBI
29	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011. View Article : Google Scholar : PubMed/NCBI
30	Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z and Wang R: The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21^WAF1/CIP1 expression. PLoS One. 8:e772932013. View Article : Google Scholar : PubMed/NCBI
31	Hou Z, Xu C, Xie H, Xu H, Zhan P, Yu L and Fang X: Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. PLoS One. 9:e1081332014. View Article : Google Scholar : PubMed/NCBI
32	Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D, Al-Daccak R and Aoudjit F: α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem. 287:17065–17076. 2012. View Article : Google Scholar : PubMed/NCBI
33	Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, Thanopoulou E, Karakantza M, Pantazis P, Spyridonidis A and Zoumbos NC: c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia. 22:1899–1908. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kweon SH, Song JH and Kim TS: Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun. 395:104–110. 2010. View Article : Google Scholar : PubMed/NCBI
35	Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
36	Fransecky L, Mochmann LH and Baldus CD: Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 3:22015. View Article : Google Scholar : PubMed/NCBI